Another Major Accomplishment for Dune Medical as it Launches its First In-Man Trial for its Revolutionary Smart Biopsy Device

ALPHARETTA, Ga.–(BUSINESS WIRE)–Dune
Medical Devices has just completed the first in-man cases for
Smart Biopsy, its percutaneous soft tissue biopsy device which leverages
the real-time tissue characterization capability of its radio-frequency
(RF) spectroscopy technology.

These first in-man cases were completed by Dr. Noemi Weissenberg,
Radiologist, at the Meir Medical Center in Kfar Saba, Israel. Utilizing
miniaturized sensors located on a core needle, Smart Biopsy generated,
in real time, electrical parameters of the sampled tissue. These
electrical parameters will be compared to histopathologic findings in
order to provide additional value with regard to improving diagnosis and
read-out.

The Smart Biopsy device represents a significant breakthrough in Dune
Medical’s quest to offer real-time, multi-cancer, diagnostic and
treatment applications. Dune Medical’s RF Spectroscopy and its
miniaturized sensor technology provide the most accurate interpretation
of electrical parameters which correlate to tissue type, and most
importantly, to the differentiation between cancer and healthy tissue.
Identifying tissue properties during the biopsy procedure enables the
physician to enhance their diagnostic capability beyond just image
guidance, potentially preventing patients the anxiety of an
underdiagnosis or an overdiagnosis. The Smart Biopsy Device and its
technology were recently featured in an article by Medical
Device and Diagnostic Industry (MD+DI).

The development of the Smart Biopsy Device was supported by the
prestigious European Union Horizon 2020 research grant that Dune Medical
received in 2016.

Dune Medical Devices CEO Lori Chmura is enthusiastic about the progress
made. “The in-man phase is the continuation of a broader and more
comprehensive clinical trial aimed at definitive tissue characterization
in the breast, Dunes first application. The collective works will be
published later this year as a revolutionary solution for enhancing
accuracy in biopsy diagnosis and guide future development of RF
Spectroscopy across the oncology spectrum. We’re thrilled to have met
this important milestone in our strategy to offer multi-cancer
applications.”

About Dune Medical Devices
“Imagine not having to wonder,
did we get it all?”
At Dune Medical Devices, we believe in reducing
the anxiety that waiting for pathology results places on a patient and
their families. Our solutions, which are developed on a
first-of-its-kind RF Spectroscopy platform, can differentiate cancerous
from healthy tissue based on electromagnetic properties, making it
possible for patients and physicians to answer the question, “did we get
it all?” For more information, contact [email protected].

Contacts

Write2Market for Dune Medical Devices
Jean-Luc Vanhulst
[email protected]
+1
(347) 453-7686